DOCSLIB.ORG

Granisetron Versus Tropisetron in the Prevention of Postoperative Nausea and Vomiting After Total Thyroidectomy

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Granisetron Versus Tropisetron in the Prevention of Postoperative Nausea and Vomiting After Total Thyroidectomy SJA_227_12R5 ORIGINAL ARTICLE Page | 107 1 1 2 2 3 Granisetron versus tropisetron in the prevention 3 4 4 5 of postoperative nausea and vomiting after total 5 6 6 7 thyroidectomy 7 8 8 9 9 10 Artemisia Papadima, 10 11 ABSTRACT 11 Stavros Gourgiotis1, 12 Background: Postoperative nausea and vomiting (PONV) are frequently encountered 12 1 13 Emmanuel Lagoudianakis , after thyroidectomy. For PONV prevention, selective serotonin 5‑hydroxytryptamine 13 2 type 3 (5‑HT ) receptor antagonists are considered one of the first‑line therapy. We 14 Apostolos Pappas , 3 14 15 Charalampos Seretis1, report on the efficiency of granisetron and tropisetron, with that of placebo on the 15 prevention of PONV in patients undergoing total thyroidectomy. Methods: One hundred 2 16 Pantelis T. Antonakis , twenty‑seven patients were divided into three groups and randomized to receive 16 17 Haridimos Markogiannakis2, intravenously, prior to induction of anesthesia, tropisetron 5 mg, or granisetron 3 mg, 17 18 Ira Makri, or normal saline. All patients received additionally 0.625 mg droperidol. All episodes of 18 postoperative PONV during the first 24 h after surgery were evaluated. Results: Nausea 19 2 19 20 Andreas Manouras visual analogue scale (VAS) score was lower in tropisetron and granisetron groups than 20 21 Departments of Anesthesiology, the control group at all measurements (P<0.01) except for the 8‑h measurement for 21 Hippocrateion Hospital, 1Surgical, tropisetron (P=0.075). Moreover, granisetron performed better than tropisetron (P<0.011 22 401 General Army Hospital of at 4 h and P<0.01 at all other points of time) apart from the 2‑h measurement. Vomiting 22 23 Athens, 2Propedeutic Surgery, occurred in 22.2%, 27.5%, and 37.5% in granisetron, tropisetron, and control groups, 23 Hippocrateion Hospital, Athens 24 respectively (P=0.43). Conclusions: The combination of the 5‑HT3 antagonists with 24 Medical School, University of droperidol given before induction of anesthesia is well tolerated and superior to droperidol 25 Athens, Athens, Greece 25 26 alone in preventing nausea but not vomiting after total thyroidectomy. 26 27 Address for correspondence: 27 28 Dr. Stavros Gourgiotis, 28 29 41 Zakinthinou Street, 15669, 29 30 Papagou, Athens, Greece. Key words: Nausea, vomiting, thyroidectomy, granisetron, tropisetron 30 E‑mail: [email protected] 31 31 32 32 33 33 34 postoperative recovery.[5,6] Uncontrolled PONV remains 34 INTRODUCTION 35 the leading cause of delayed discharge or unexpected 35 36 readmission after ambulatory surgery.[7] Furthermore, it is 36 37 Postoperative nausea and vomiting (PONV) are two 37 of the most common and distressing complications a risk factor for postoperative bleeding, a complication of 38 particular concern due to the potential for neck hematoma 38 after anesthesia and surgery, and may lead to serious [5,8] 39 [1,2] formation and airway obstruction. Its incidence varies, 39 40 postoperative complications. The overall incidence of 40 PONV has been reported to be between 20% and 30%,[3] according to numerous anesthesia‑ and non–anesthesia‑ 41 related factors, yet remaining quite frequent.[9,10] PONV, 41 42 whereas reported incidence of PONV is between 63% and 42 84% in patients scheduled for thyroidectomy.[4] regardless of clinical severity, is an important issue from 43 the patients’ point of view[11]; improvement of the quality 43 44 44 PONV may represent the principal source of discomfort of care should therefore include reduction of the incidence 45 and severity of PONV.[12] 45 46 of the entire procedure and the most unpleasant aspect of 46 47 47 Access this article online Prevention strategies with drugs and nonpharmacologic 48 [13‑17] 48 Quick Response Code: interventions have been studied extensively. Serotonin 49 Website: receptor antagonists, particularly 5‑hydroxytryptamine 49 50 www.saudija.org 50 type 3 (5‑HT3) receptor antagonists, are an essential 51 constituent of prophylactic or rescue treatment of PONV 51 [18] 52 DOI: in patients at risk, according to respective guidelines. The 52 53 *** theoretic basis for these antagonists is sound, since they 53 54 54 exert their effects by binding to the 5‑HT3 receptor in the Saudi Journal of Anaesthesia Vol. 7, Issue 1, January-March 2013 Papadima, et al.: Prevention of postoperative nausea and vomiting Page | 108 1 chemoreceptor trigger zone and at vagal afferent neurons induction of anesthesia. All i.v. regimens were diluted with 1 2 in the gastrointestinal tract. Moreover, their side effects are N/S 0.9% to a volume of 5 mL. Upon entrance to the 2 3 minimal and especially their lack of sedation properties operative room schedule, a code number was assigned to 3 4 makes them particularly suitable for ambulatory surgery.[19] each patient. The anesthesiologist and staff nurses, as well 4 5 as the operative team, were blinded to the administered 5 6 Preclinical studies have indicated possible differences agent. 6 7 between tropisetron and granisetron.[20] Unlike granisetron 7 8 (an indazole), tropisetron is an indole compound. It has Protocol 8 9 high affinity and specificity for 5‑HT3 receptors but appears The anesthetic technique was identical in all patients. 9 10 to have a weak antagonistic effect on 5‑HT4 receptors, Patients fasted for at least 12 h preoperatively and received 10 11 whereas granisetron show no affinity for any other than oral premedication with 1.5 mg of bromazepam and 11 12 5‑HT3 receptors. Metabolism of tropisetron occurs 40 mg of omeprazol the night before surgery and 3 h 12 13 predominantly in the liver. before the operation. Ten minutes before induction to 13 14 anesthesia, all patients received 2.5 mg of midazolam and 14 15 The aim of this prospective, randomized, double‑blind, then parecoxib (40 mg/2 mL i.v.). In all cases, propofol 15 16 placebo‑controlled study was to evaluate and compare the 2 mg/kg and remifentanil 1 µg/kg were the induction 16 17 efficiency of tropisetron for preventing PONV compared drugs and cis‑atracurium 0.2 mg/kg was administered 17 18 with that of granisetron or placebo in patients undergoing for muscle relaxation. Meperidine (1 mg/kg) was 18 19 total thyroidectomy during the first 24 postoperative hours. intramuscularly (i.m.) administered after induction, and 19 20 maintenance of anesthesia was achieved with sevoflurane 20 21 METHODS minimum alveolar concentration (MAC) 1.0%‑1.5% in a 21 22 22 mixture of O2 to air and remifentanil in continuous infusion 23 Patients in this study were prospectively randomized (0.15‑0.2 µg/kg/min). 23 24 and data were prospectively recorded; then, data were 24 25 retrospectively collected and analyzed. After obtaining Nasogastric decompression was not employed, as patients 25 26 approval from the Ethical Committee of our hospital, were also included in a clinical audit, evaluating the 26 27 and after written informed consent, male or female necessity of nasogastric tube insertion in thyroid surgery. 27 28 patients scheduled for total thyroidectomy under general Intraoperative monitoring included electrocardiogram, 28 29 anesthesia from January 2009 until January 2010 were heart rate, arterial blood pressure (noninvasive method), 29 30 30 evaluated for study enrollment. Inclusion criteria were end expiratory CO2, O2 saturation, minute/volume, tidal 31 age between 18 and 75 years and American Society of volume, respiratory rate, airway pressures, and MAC 31 32 Anesthesiologists (ASA) physical status I or II. sevoflurane. Pulmonary ventilation was performed under 32 33 intermittent positive pressure ventilation (IPPV) with a 33 34 mixture of oxygen and air, maintaining fractional inspired 34 Exclusion criteria were known hypersensitivity to 5‑HT3 35 35 drugs, body mass index (BMI) ≥35, significant systemic oxygen (FiO2) at 0.5. Ventilation was adjusted to keep the 36 36 diseases, history of atypical or known gastrointestinal end‑tidal CO2 between 35 and 40 mmHg. Blood pressure 37 problems and/or previous gastrointestinal operations (not and heart rate variations were maintained within 20% of 37 38 including appendectomy), menstruation on admission, preoperative values by adjusting anesthetic depth, fluid 38 39 39 history of tinnitus, and reception of steroids, H2 antagonists, replacement, and vasoactive drug dosages. Adductor 40 anticholinergics, antihistamines, butyrophenones, pollicis stimulation over the ulnar nerve at the wrist was the 40 41 phenothiazines, or metoclopramide 24 h before admission. standard method of monitoring neuromuscular function. 41 42 Patients with an intrathoracic goiter or undergoing a Train‑of‑four (TOF) stimulations were used to assess the 42 43 difficult endotracheal intubation (more than two attempts presence of a residual neuromuscular block. No alternative 43 44 at tracheal intubation) were also excluded. No grants or forms of analgesic were administered to the patients. 44 45 funds from pharmaceutical companies were acquired. Atropine 1 mg and neostigmine 2.4 mg were used to 45 46 reverse residual neuromuscular blockade. All patients were 46 47 Study patients were enrolled and randomized with extubated on the operating table and were transported to 47 48 Bernoulli tables (which allow “complete” or “unrestricted” the postanesthesia care unit (PACU) with supplemental 48 49 randomization, minimizing both selection and accidental oxygen in consciousness with adequate self‑maintained 49 50 biases), to receive prophylactic either intravenous (i.v.) respiratory and cardiovascular function. 50 51 tropisetron 5 mg (1 mg/mL) (T group), i.v. granisetron 51 52 3 mg (G group), or i.v. 5 mL normal saline (N/S) Postoperative care 52 53 0.9% (control group, C group) in combination with Postoperatively, patients were observed for 24 h. A team 53 54 0.625 mg droperidol, approximately 5 min before of specially trained nurse anesthetists, blinded to the 54 Vol. 1, Issue 1, January-March 2013 Saudi Journal of Anaesthesia Papadima, et al.: Prevention of postoperative nausea and vomiting Page | 109 1 patient’s group, collected postoperative data.
Load more

Recommended publications
  • Evidence for the Involvement of Spinal Cord 1 Adrenoceptors in Nitrous
    Anesthesiology 2002; 97:1458–65 © 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Evidence for the Involvement of Spinal Cord ␣ 1 Adrenoceptors in Nitrous Oxide–induced Antinociceptive Effects in Fischer Rats Ryo Orii, M.D., D.M.Sc.,* Yoko Ohashi, M.D.,* Tianzhi Guo, M.D.,† Laura E. Nelson, B.A.,‡ Toshikazu Hashimoto, M.D.,* Mervyn Maze, M.B., Ch.B.,§ Masahiko Fujinaga, M.D.ʈ Background: In a previous study, the authors found that ni- opioid peptide release in the brain stem, leading to the trous oxide (N O) exposure induces c-Fos (an immunohisto- 2 activation of the descending noradrenergic inhibitory chemical marker of neuronal activation) in spinal cord ␥-ami- nobutyric acid–mediated (GABAergic) neurons in Fischer rats. neurons, which results in modulation of the pain–noci- 1 In this study, the authors sought evidence for the involvement ceptive processing in the spinal cord. Available evi- Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/97/6/1458/337059/0000542-200212000-00018.pdf by guest on 01 October 2021 ␣ of 1 adrenoceptors in the antinociceptive effect of N2O and in dence suggests that at the level of the spinal cord, there activation of GABAergic neurons in the spinal cord. appear to be at least two neuronal systems that are Methods: Adult male Fischer rats were injected intraperitone- involved (fig. 1). In one of the pathways, activation of ally with ␣ adrenoceptor antagonist, ␣ adrenoceptor antago- 1 2 ␣ nist, opioid receptor antagonist, or serotonin receptor antago- the 2 adrenoceptors produces either direct presynaptic nist and, 15 min later, were exposed to either air (control) or inhibition of neurotransmitter release from primary af- 75% N2O.
    [Show full text]
  • Ondansetron Does Not Attenuate the Analgesic Efficacy of Nefopam Kai-Zhi Lu 1*, Hong Shen 2*, Yan Chen 1, Min-Guang Li 1, Guo-Pin Tian 1, Jie Chen 1
    Int. J. Med. Sci. 2013, Vol. 10 1790 Ivyspring International Publisher International Journal of Medical Sciences 2013; 10(12):1790-1794. doi: 10.7150/ijms.5386 Research Paper Ondansetron Does Not Attenuate the Analgesic Efficacy of Nefopam Kai-zhi Lu 1*, Hong Shen 2*, Yan Chen 1, Min-guang Li 1, Guo-pin Tian 1, Jie Chen 1 1. Department of Anaesthesiology, Southwest Hospital, Third Military Medical University, Chongqing 400038, China; 2. Department of Radiology, Chongqing Fifth Hospital, Chongqing.400062, China. * These authors contributed equally to this work. Corresponding author: Dr. Jie Chen: Department of Anaesthesiology, Southwest Hospital, Third Military Medical University, Gaotanyan 19 Street, Shapingba, Chongqing 400038, China. Tel: 0086-23-68754197. Fax: 0086-23-65463285. E-mail: [email protected] © Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/ licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited. Received: 2012.10.15; Accepted: 2013.10.17; Published: 2013.10.29 Abstract Objectives: The aim of this study was to investigate if there is any interaction between ondansetron and nefopam when they are continuously co-administrated during patient-controlled intravenous analgesia (PCIA). Methods: The study was a prospective, randomized, controlled, non-inferiority clinical trial com- paring nefopam-plus-ondansetron to nefopam alone. A total of 230 postoperative patients using nefopam for PCIA, were randomly assigned either to a group receiving continuous infusion of ondansetron (Group O) or to the other group receiving the same volume of normal saline con- tinuously (Group N).
    [Show full text]
  • 2D6 Substrates 2D6 Inhibitors 2D6 Inducers
    Physician Guidelines: Drugs Metabolized by Cytochrome P450’s 1 2D6 Substrates Acetaminophen Captopril Dextroamphetamine Fluphenazine Methoxyphenamine Paroxetine Tacrine Ajmaline Carteolol Dextromethorphan Fluvoxamine Metoclopramide Perhexiline Tamoxifen Alprenolol Carvedilol Diazinon Galantamine Metoprolol Perphenazine Tamsulosin Amiflamine Cevimeline Dihydrocodeine Guanoxan Mexiletine Phenacetin Thioridazine Amitriptyline Chloropromazine Diltiazem Haloperidol Mianserin Phenformin Timolol Amphetamine Chlorpheniramine Diprafenone Hydrocodone Minaprine Procainamide Tolterodine Amprenavir Chlorpyrifos Dolasetron Ibogaine Mirtazapine Promethazine Tradodone Aprindine Cinnarizine Donepezil Iloperidone Nefazodone Propafenone Tramadol Aripiprazole Citalopram Doxepin Imipramine Nifedipine Propranolol Trimipramine Atomoxetine Clomipramine Encainide Indoramin Nisoldipine Quanoxan Tropisetron Benztropine Clozapine Ethylmorphine Lidocaine Norcodeine Quetiapine Venlafaxine Bisoprolol Codeine Ezlopitant Loratidine Nortriptyline Ranitidine Verapamil Brofaramine Debrisoquine Flecainide Maprotline olanzapine Remoxipride Zotepine Bufuralol Delavirdine Flunarizine Mequitazine Ondansetron Risperidone Zuclopenthixol Bunitrolol Desipramine Fluoxetine Methadone Oxycodone Sertraline Butylamphetamine Dexfenfluramine Fluperlapine Methamphetamine Parathion Sparteine 2D6 Inhibitors Ajmaline Chlorpromazine Diphenhydramine Indinavir Mibefradil Pimozide Terfenadine Amiodarone Cimetidine Doxorubicin Lasoprazole Moclobemide Quinidine Thioridazine Amitriptyline Cisapride
    [Show full text]
  • 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: the Iceberg Still Lies Beneath the Surface
    1521-0081/71/3/383–412$35.00 https://doi.org/10.1124/pr.118.015487 PHARMACOLOGICAL REVIEWS Pharmacol Rev 71:383–412, July 2019 Copyright © 2019 by The Author(s) This is an open access article distributed under the CC BY-NC Attribution 4.0 International license. ASSOCIATE EDITOR: JEFFREY M. WITKIN 5-HT3 Receptor Antagonists in Neurologic and Neuropsychiatric Disorders: The Iceberg Still Lies beneath the Surface Gohar Fakhfouri,1 Reza Rahimian,1 Jonas Dyhrfjeld-Johnsen, Mohammad Reza Zirak, and Jean-Martin Beaulieu Department of Psychiatry and Neuroscience, Faculty of Medicine, CERVO Brain Research Centre, Laval University, Quebec, Quebec, Canada (G.F., R.R.); Sensorion SA, Montpellier, France (J.D.-J.); Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran (M.R.Z.); and Department of Pharmacology and Toxicology, University of Toronto, Toronto, Ontario, Canada (J.-M.B.) Abstract. ....................................................................................384 I. Introduction. ..............................................................................384 II. 5-HT3 Receptor Structure, Distribution, and Ligands.........................................384 A. 5-HT3 Receptor Agonists .................................................................385 B. 5-HT3 Receptor Antagonists. ............................................................385 Downloaded from 1. 5-HT3 Receptor Competitive Antagonists..............................................385 2. 5-HT3 Receptor
    [Show full text]
  • Effects of Dexfenfluramine and 5-HT3 Receptor Antagonists on Stress-Induced Reinstatement of Alcohol Seeking in Rats
    Psychopharmacology (2006) 186: 82–92 DOI 10.1007/s00213-006-0346-y ORIGINAL INVESTIGATION Anh Dzung Lê . Douglas Funk . Stephen Harding . W. Juzytsch . Paul J. Fletcher . Yavin Shaham Effects of dexfenfluramine and 5-HT3 receptor antagonists on stress-induced reinstatement of alcohol seeking in rats Received: 29 October 2005 / Accepted: 3 February 2006 / Published online: 7 March 2006 # Springer-Verlag 2006 Abstract Rationale and objectives: We previously found 0.1 mg/kg, i.p) on reinstatement induced by 10 min of that systemic injections of the 5-HT uptake blocker intermittent footshock (0.8 mA) was determined. fluoxetine attenuate intermittent footshock stress-induced Results: Systemic injections of dexfenfluramine, ondan- reinstatement of alcohol seeking in rats, while inhibition of setron or tropisetron attenuated footshock-induced rein- 5-HT neurons in the median raphe induces reinstatement statement of alcohol seeking. Injections of dexfenflur- of alcohol seeking. In this study, we further explored the amine, ondansetron, or tropisetron had no effect on role of 5-HT in footshock stress-induced reinstatement of extinguished lever responding in the absence of alcohol seeking by determining the effects of the 5-HT footshock. Conclusions: The present results provide releaser and reuptake blocker dexfenfluramine, and the 5- additional support for the hypothesis that brain 5-HT HT receptor antagonists ondansetron and tropisetron, which systems are involved in stress-induced reinstatement of decrease alcohol self-administration and anxiety-like re- alcohol seeking. The neuronal mechanisms that potentially sponses in rats, on this reinstatement. Methods: Different mediate the unexpected observation that both stimulation groups of male Wistar rats were trained to self-administer of 5-HT release and blockade of 5-HT3 receptors attenuate alcohol (12% v/v) for 28–31 days (1 h/day, 0.19 ml footshock-induced reinstatement are discussed.
    [Show full text]
  • Antidepressant Effect of the Interaction of Fluoxetine with Granisetron
    5108 EXPERIMENTAL AND THERAPEUTIC MEDICINE 18: 5108-5111, 2019 Antidepressant effect of the interaction of fluoxetine with granisetron MIHNEA COSTESCU1*, HORIA PAUNESCU1*, OANA ANDREIA COMAN1*, LAURENȚIU COMAN2* and ION FULGA1* 1Department of Pharmacology and Pharmacotherapy, Faculty of Medicine; 2Department of Physiology, Faculty of Pharmacy, UMF Carol Davila, 050474 Bucharest, Romania Received August 30, 2019; Accepted October 2, 2019 DOI: 10.3892/etm.2019.8141 Abstract. Selective serotonin reuptake inhibitors (SSRIs) may Introduction produce digestive side effects such as nausea and vomiting, diarrhoea and decreased appetite. These side effects are Some antidepressants and some antipsychotics act as antago- determined by the increase in serotonin availability at 5-HT3 nists on the 5-HT3 receptor. This receptor has binding sites receptors. Granisetron, a serotonin 5-HT3 receptor antago- for antidepressant and antipsychotic drugs, so that the 5-HT3 nist, is expected to antagonize the digestive adverse effects receptor is a therapeutic target in the treatment of depression of serotonin reuptake inhibitors, but the question is to what and psychosis as an additional mechanism to the already extent granisetron influences the antidepressant effect of these known classical ones (1). substances. The aim of this study was to determine the dose 5-HT3 receptors belong to the superfamily of receptors of fluoxetine that has an antidepressant effect in the Porsolt coupled to ion channels, structurally similar to GABA A test, and the interaction between fluoxetine and granisetron receptors, nicotinic receptors and glycine receptors. Localized with respect to the antidepressant effect in this test. In experi- in central and peripheral neurons, they generate rapid depolar- ment 1, fluoxetine was antidepressant only at 20 mg/kg body ization resulting from the opening of cationic channels (Na+, K+ weight (bw).
    [Show full text]
  • Nausea and Vomiting After Strabismus-Surgery: a Randomized Comparison of Isoflurane, Enflurane, Sevoflurane and Propofol
    The Open Clinical Trials Journal, 2009, 1, 1-6 1 Open Access Nausea and Vomiting After Strabismus-Surgery: A Randomized Comparison of Isoflurane, Enflurane, Sevoflurane and Propofol P. Kranke*,1, C.C. Apfel2, T. Papenfuss1, T. Metterlein1, F. Schuster1, R. Muellenbach1, S. Rauch1 1 and N. Roewer 1Department of Anesthesia and Critical Care, University Hospitals of Würzburg, Oberdürrbacher Str. 6, D-97080 Wuerzburg, Germany 2Perioperative Clinical Research Core, Department of Anesthesiology and Perioperative Care, University of California, San Francisco, California, USA Abstract: Background: Previous studies reported that propofol anesthesia is an effective means of preventing postoperative nausea and vomiting (PONV) after different types of surgeries. The present analysis of a large antiemetic trial is intend to compare propofol versus isoflurane, enflurane or sevoflurane with respect to the incidences of PONV after strabismus surgery. Methods: 238 ASA I - III inpatients, aged 4-65 years were randomly assigned to receive either isoflurane (group I, n = 60), enflurane (group E, n = 59), sevoflurane (group S, n = 59) or propofol (group P, n = 60) for maintenance as a subgroup of a larger trial of factorial design to investigate interventions to reduce PONV. After opioid application, patients in the inhalational groups (group I, E and S) had anesthesia induced with thiopental, those in group P received propofol for induction. Tracheal intubation was facilitated with succinylcholine. Patients were ventilated with N2O/O2 2:1. Incidence and severity of PONV as well as the need for antiemetic rescue treatment were studied during the first 24 hours after anesthesia. Paracetamol and tramadol was given to treat postoperative pain.
    [Show full text]
  • Serotonin and Thermoregulation Physiologic and Pharmacologic Aspects of Control Revealed by Intravenous M-CPP in Normal Human Subjects Paul]
    ~!''"~! f'('-'t)•V( ~1.t, .. !LSI \'ILR Serotonin and Thermoregulation Physiologic and Pharmacologic Aspects of Control Revealed by Intravenous m-CPP in Normal Human Subjects Paul]. Schwartz, M.D., Thomas A. Wehr, M.D., Norman E. Rosenthal, M.D., John]. Bartko, Ph.D., Dan A. Oren, M.D., Christopher Luetke, B.S., and Dennis L. Murphy, M. D. Mcta-c/1lorophenylpipera:i11c (111-CPP), 11 probe of crntml tlze effector mechanism primarily responsible for m-CPP­ serotonergic function, elevaft's corr /e111perat11re 111 induced core hyperthermia is increased metabolic rodents, nonhuman primates, and humans uia serotoni11 t/1cnnogenesis. Individual differences in the magnitude of receptor-mediated mechanisms. To further characterize t/1c hyperthermia were independent of m-CPP plasma the thermoregulaton1 aspects of this response, ,ue studied nmcentrations but were found to be linearly correlated 16 healthy uolunteers using multiple core and skin with the level of the previous night's core rectal temperature recording sites. Compared tu placebo, temperature minimum and mean. It appears that m-CPP intravenous 111-CPP (0. 08 mgikg) produced statisticaU11 adiuates a mode of metabolic thennogenesis governed by significant bipliasic changes in rectal lt'mperatu re, a noctu mally sensiti'ue proportional control mechanism. characterized by initial hypothermia ( - 0. ()4' Cat 1 The operation of such a proportional controller is minutes) followed by progrrssiz•e Jz11prrt/1em1ia I+ U. l-; (_ clza ractcrized by a set point and a gain, and has been at 90 minutes). 111-CPP also produced s1gnitica11t implicated in the general economy of mammalian energy increases in plasma 11urepimplz rinc I oncc11t ratio11s.
    [Show full text]
  • Pharmacokinetics and Pharmacology of Drugs Used in Children
    Drug and Fluid Th erapy SECTION II Pharmacokinetics and Pharmacology of Drugs Used CHAPTER 6 in Children Charles J. Coté, Jerrold Lerman, Robert M. Ward, Ralph A. Lugo, and Nishan Goudsouzian Drug Distribution Propofol Protein Binding Ketamine Body Composition Etomidate Metabolism and Excretion Muscle Relaxants Hepatic Blood Flow Succinylcholine Renal Excretion Intermediate-Acting Nondepolarizing Relaxants Pharmacokinetic Principles and Calculations Atracurium First-Order Kinetics Cisatracurium Half-Life Vecuronium First-Order Single-Compartment Kinetics Rocuronium First-Order Multiple-Compartment Kinetics Clinical Implications When Using Short- and Zero-Order Kinetics Intermediate-Acting Relaxants Apparent Volume of Distribution Long-Acting Nondepolarizing Relaxants Repetitive Dosing and Drug Accumulation Pancuronium Steady State Antagonism of Muscle Relaxants Loading Dose General Principles Central Nervous System Effects Suggamadex The Drug Approval Process, the Package Insert, and Relaxants in Special Situations Drug Labeling Opioids Inhalation Anesthetic Agents Morphine Physicochemical Properties Meperidine Pharmacokinetics of Inhaled Anesthetics Hydromorphone Pharmacodynamics of Inhaled Anesthetics Oxycodone Clinical Effects Methadone Nitrous Oxide Fentanyl Environmental Impact Alfentanil Oxygen Sufentanil Intravenous Anesthetic Agents Remifentanil Barbiturates Butorphanol and Nalbuphine 89 A Practice of Anesthesia for Infants and Children Codeine Antiemetics Tramadol Metoclopramide Nonsteroidal Anti-infl ammatory Agents 5-Hydroxytryptamine
    [Show full text]
  • Tropisetron-AFT
    Tropisetron-AFT Tropisetron hydrochloride equivalent to Tropisetron 2mg/2 mg and 5 mg/5 mL, solution for injection and infusion Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Tropisetron-AFT. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist. You should ensure that you speak to your pharmacist or doctor to obtain the most up to date information on Tropisetron-AFT. All medicines have risks and benefits. Your doctor has weighed the risks of you having this medicine against the benefits they expect it will provide. If you have any concerns about this medicine, ask your doctor or pharmacist. Keep this leaflet with the medicine. You may need to read it again. What Tropisetron-AFT is used for Tropisetron-AFT is used to prevent nausea (feeling sick) and vomiting caused by surgery and by cancer chemotherapy. The active ingredient in Tropisetron-AFT is tropisetron. It works by stopping the action of a substance in the body called serotonin that is thought to cause the nausea and vomiting. Ask your doctor if you have any questions about why this medicine has been prescribed for you. Your doctor may have prescribed it for another reason. Tropisetron-AFT is only available with a doctor's prescription. It is not addictive. There is not enough information to recommend its use in children. Before you are given Tropisetron-AFT When you must not be given it Do not use Tropisetron-AFT if you have ever had an allergy to: tropisetron (the active ingredient in Tropisetron-AFT) any of the other ingredients listed at the end of this leaflet similar medicines such as ondansetron, granisetron and dolasetron Some of the symptoms of an allergic reaction include shortness of breath, wheezing or difficulty breathing; swelling of the face, lips, tongue or other parts of the body; rash, itching or hives on the skin.
    [Show full text]
  • Albert Hofmann's Pioneering Work on Ergot Alkaloids and Its Impact On
    BIRTHDAY 83 CHIMIA 2006, 60, No. 1/2 Chimia 60 (2006) 83–87 © Schweizerische Chemische Gesellschaft ISSN 0009–4293 Albert Hofmann’s Pioneering Work on Ergot Alkaloids and Its Impact on the Search of Novel Drugs at Sandoz, a Predecessor Company of Novartis Dedicated to Dr. Albert Hofmann on the occasion of his 100th birthday Rudolf K.A. Giger* and Günter Engela Abstract: The scientific research on ergot alkaloids is fundamentally related to the work of Dr. Albert Hofmann, who was able to produce, from 1935 onwards, a number of novel and valuable drugs, some of which are still in use today. The complex chemical structures of ergot peptide alkaloids and their pluripotent pharmacological activity were a great challenge for Dr. Hofmann and his associates who sought to unravel the secrets of the ergot peptide alkaloids; a source of inspiration for the design of novel, selective and valuable medicines. Keywords: Aminocyclole · Bromocriptine Parlodel® · Dihydroergotamine Dihydergot® · Dihydro ergot peptide alkaloids · Ergobasin/ergometrin · Ergocornine · Ergocristine · α- and β-Ergocryptine · Ergolene · Ergoline · Ergoloid mesylate Hydergine® · Ergotamine Gynergen® · Ergotoxine · Lisuride · Lysergic acid diethylamide LSD · Methylergometrine Methergine® · Methysergide Deseril® · Paspalic acid · Pindolol Visken® · Psilocybin · Serotonin · Tegaserod Zelmac®/Zelnorm® · Tropisetron Navoban® Fig. 1. Albert Hofmann in 1943, 1979 and 2001 (Photos in 2001 taken by J. Zadrobilek and P. Schmetz) Dr. Albert Hofmann (Fig. 1), born on From the ‘Ergot Poison’ to *Correspondence: Dr. R.K.A. Giger January 11, 1906, started his extremely Ergotamine Novartis Pharma AG NIBR Global Discovery Chemistry successful career in 1929 at Sandoz Phar- Lead Synthesis & Chemogenetics ma in the chemical department directed The scientific research on ergot alka- WSJ-507.5.51 by Prof.
    [Show full text]
  • Effects of SHT3 Receptor Antagonism by Tropisetron on the Sleep EEG
    NEUROPSYCHOPHARMACOLOGY 1994-VOL. 11, NO.2 101 Effects of SHT3 Receptor Antagonism by Tropisetron on the Sleep EEG and on Nocturnal Hormone Secretion Barbara Rothe, M.D., Jurgen Guldner, M.D., Edgar Hohlfeldt, M.D., Christoph]. Lauer, Ph.D., Thomas Pollmiicher, M.D., Florian Holsboer, M.D., Ph.D., and Axel Steiger, M.D. Two dosages (5 mg and 25 mg) of the selective 5HT3 the first part of the sleep period, and stage 2 was receptor antagonist tropisetron (lCS 205-930) were decreased during the total night. In addition, plasma administered to healthy male controls, and the effects on cortisol levels increased earlier than under placebo, and the sleep EEG and nocturnal secretory activity of growth plasma GH levels were reduced in the second part of the hormone (GH) and cortisol were evaluated. The lower night. Thus, only discrete effects of tropisetron upon dosage was administered to four subjects and the higher sleep-endocrine activity were noted, making it unlikely dosage to eight on 5 consecutive days, preceded and that serotoninergic neurotransmission exerts its well­ followed by 2 days of placebo treatment. After 25 mg of documented effects upon sleep through 5HT3 receptors. tropisetron, there was a slight increase in REM sleep in [Neuropsychopharmacology 11:101-106, 1994J KEY WORDS: 5HT3 receptor; Tropisetron; Sleep EEG; the view that serotoninergic stimulation produces be­ Growth hormone; Cortisol havioral sleep accompanied by slow waves in the neo­ Research in animals and humans indicates that sero­ cortex (Robertson et al. 1991). However, it remained toninergic and catecholarninergic neurotransmission undisputed that serotoninergic neurotransrnissionis es­ play an important role in regulating behavior, spe­ sential for sleep regulation in general.
    [Show full text]